The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL.
 
Marco Montillo
Honoraria - Abbvie; AstraZeneca; Gilead Sciences; Janssen; Roche; Verastem
Consulting or Advisory Role - Abbvie; Janssen
Speakers' Bureau - Abbvie; Janssen
 
Davide Rossi
Honoraria - Abbvie; Gilead Sciences; Janssen; Janssen; Roche
Research Funding - Abbvie (Inst); Gilead Sciences (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Janssen
 
Emanuele Zucca
Honoraria - Abbvie; Gilead Sciences; Janssen; Roche
Consulting or Advisory Role - Abbvie; Janssen; Roche
Speakers' Bureau - Abbvie; Janssen
 
Anna Maria Frustaci
No Relationships to Disclose
 
Stefano Pileri
No Relationships to Disclose
 
Franco Cavalli
Honoraria - Abbvie; Gilead Sciences; Janssen; Roche
Speakers' Bureau - Abbvie; Janssen; Roche
 
Alessandra Tedeschi
Honoraria - Abbvie; BeiGene; Janssen; Sunesis Pharmaceuticals
Consulting or Advisory Role - Abbvie; BeiGene; Janssen
Speakers' Bureau - Abbvie; BeiGene; Janssen